肾母细胞瘤组织中DNA倍体、SPF和NM23表达的检测  

Detection of DNA ploidy,S-phase fraction and expression of NM23 in nephroblastoma tissue

作　　者：夏宗江[1] 刘秋亮[1] 王家祥[1] 

机构地区：[1]郑州大学第一附属医院外科,郑州450052

出　　处：《郑州大学学报（医学版）》2007年第1期142-144,共3页Journal of Zhengzhou University(Medical Sciences)

摘　　要：目的:检测肾母细胞瘤组织中DNA倍体、SPF和NM23的表达。方法:选取35例肾母细胞瘤组织和10例正常肾组织,采用流式细胞仪(FCM)检测DNA倍体、SPF,免疫组化SP法检测NM23的表达。结果:肾母细胞瘤组织中DNA异倍体率、SPF均高于正常对照组,差异有统计学意义。NM23在正常对照组的阳性表达率(90.0%)明显高于肾母细胞瘤组织(31.4%)。DNA倍体与NM23呈负相关。结论:联合检测DNA倍体、SPF、NM23可为评价肾母细胞瘤的生物学行为和临床治疗提供一定的依据。Aim： To detect DNA ploidy, S-phase fraction（SPF）, and the expression of NM23 in nephroblastoma tissue. Methods：Thirty five cases of nephroblastoma and 10 cases of normal renal tissue were chosen. DNA ploidy and SPF was detected by flow cytometry and the expression of NM23, by immunohistochemical staining. Results： Significiant difference was found between normal renal tissue and nephroblastoma tissue in aneuploidy rate and SPF. The positive rate of NM23 expression in control group and nephroblastoma tissue were 90.0% and 31.4%, respectively, and there was significant difference （P 〈 0. 05）. DNA ploidy was negatively correlated with the expression of NM23, ConclusioN; Combining detection of DNA ploidy, SPF, and the expression of NM23 may be useful to evaluate the biological behavior of nephroblastoma.

关 键 词：肾母细胞瘤 DNA倍体 SPF NM23 

分 类 号：R656[医药卫生—外科学] R692[医药卫生—临床医学]